Preventing nausea from Trastuzumab Rezetecan with two anti-nausea drugs
Part of Digestive system clinical trials.
This trial tests whether a combination of two anti-nausea drugs (fosrolapitant and palonosetron) can better prevent nausea and vomiting caused by Trastuzumab Rezetecan. If you are starting this cancer treatment, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive Trastuzumab Rezetecan (a cancer treatment).
- You are 18 years of age or older.
- You are able to get up and care for yourself (performance status 0–2).
- You have no major fluid buildup in your belly or around your lungs.
- Your heart, liver, kidneys, and blood counts are working well (tests will confirm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of megestrol acetate to prevent nausea and vomiting caused by chemotherapy in people with advanced stomach cancer who haven't had chemo before. It's for those starting a specific chemo combo that includes a PD-1 inhibitor and CAPOX.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
This trial tests a new antibody-drug combination called trastuzumab rezetecan (SHR-A1811) in people with a specific type of breast cancer (HER2-low) that has spread and is causing serious organ problems (visceral crisis). The goal is to see if this treatment can help when organs like the liver or lungs are rapidly failing due to the cancer.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This study tests if two medicines given together, fosaprepitant and palonosetron, can prevent nausea and vomiting caused by strong chemotherapy given over several days. It's for people who have never had chemo before and are about to start a multi-day treatment for a solid tumor.
Hear when a new Chemotherapy-Induced Nausea and Vomiting (CINV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.